Last Published:  07/31/19 10:05:33 AM (Central)
Short Title: Mars 600/900 Sim II
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Other:
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Solicited
Aims:



Specific Aims:

  • Aim 1 (Cancer): Determine impact of a simulated 600 day Mars mission exposure on radiation carcinogenesis including tumor burden, spectrum, latency, progression, and aggressiveness.

  •  

  • Aim 2 (Cancer): Determine impact of a simulated 900 day Mars mission exposure, including complex secondary environment found on Mars Surface, on radiation carcinogenesis including tumor burden, spectrum, latency, progression, and aggressiveness.

  •  

  • Aim 3 (CVD/CNS): Determine impact of a simulated 600 day Mars mission exposure on cardiovascular and late neurodegenerative CNS diseases.

  •  

  • Aim 4 (CVD/CNS): Determine impact of a simulated 900 day Mars mission exposure, including complex secondary environment found on Mars Surface cardiovascular and late neurodegenerative CNS diseases.

  •  

  • Aim 5 (Cross Risk): Validate biomarker approaches for in mission surveillance during Mars 600 and 900 mission simulation.

  •  

Studies will focus on doses and dose rates seen on a 600 day free space transit simulating Mars flyby or opposition-class, short stay mission as well as a 900 day conjunction-class, long stay mission on the surface of Mars.




Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
GapCBS-CNS - 2: Does space radiation exposure elicit key events in adverse outcome pathways associated with neurological diseases? What are the key events or hallmarks, their time sequence and their associated biomarkers (in-flight or post-flight)?
GapCBS-CNS - 3: How does individual susceptibility including hereditary pre-disposition (e.g. Alzheimer’s, Parkinson’s, apoE allele) and prior CNS injury (e.g. concussion, chronic inflammation or other) alter significant CNS risks? Does individual susceptibility modify possible threshold doses for these risks in a significant way?
GapCBS-CNS - 5: How can new knowledge and data from molecular, cellular, tissue and animal models of acute CNS adverse changes or clinical human data, including altered motor and cognitive function and behavioral changes be used to estimate acute CNS risks to astronauts from GCR and SPE?
GapCNS - 6: How can new knowledge and data from molecular, cellular, tissue and animal models of late CNS risks or clinical human data be used to estimate late CNS risks to astronauts from GCR and SPE?
You are here!TaskMars 600/900 Simulation II: Large Animal Chronic Studies

RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
GapCBS-CNS - 2: Does space radiation exposure elicit key events in adverse outcome pathways associated with neurological diseases? What are the key events or hallmarks, their time sequence and their associated biomarkers (in-flight or post-flight)?
GapCBS-CNS - 3: How does individual susceptibility including hereditary pre-disposition (e.g. Alzheimer’s, Parkinson’s, apoE allele) and prior CNS injury (e.g. concussion, chronic inflammation or other) alter significant CNS risks? Does individual susceptibility modify possible threshold doses for these risks in a significant way?
GapCBS-CNS - 5: How can new knowledge and data from molecular, cellular, tissue and animal models of acute CNS adverse changes or clinical human data, including altered motor and cognitive function and behavioral changes be used to estimate acute CNS risks to astronauts from GCR and SPE?
You are here!TaskMars 600/900 Simulation II: Large Animal Chronic Studies

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
GapDegen - 1: How can tissue specific experimental models be developed for the major degenerative tissue risks, including cardiovascular, cerebrovascular, lens, and other tissue systems (e.g. immune, endocrine, respiratory and/or digestive) in order to estimate space radiation risks for degenerative diseases?
GapDegen - 2: What are the adverse outcome pathways associated with degenerative tissues changes in the cardiovascular, cerebrovascular, lens, immune, digestive, endocrine, and other tissue systems? What are the key events or hallmarks, their time sequence, and their associated biomarkers?
GapDegen - 3: What are the progression rates and latency periods for radiation-induced degenerative diseases, and how do progression rates depend on age, sex, radiation type, or other physiological or environmental factors?
GapDegen - 5: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, animal results, or clinical human data to predict degenerative tissue risks in astronauts? How can human epidemiology data best support these procedures or models?
You are here!TaskMars 600/900 Simulation II: Large Animal Chronic Studies

RiskRisk of Radiation Carcinogenesis
You are here!TaskMars 600/900 Simulation II: Large Animal Chronic Studies